 Despite significant antiemetic advances, almost 50 % of treated cancer patients still experience nausea and vomiting (N&V). The goal of antiemetic therapy—complete prevention of treatment-induced nausea and/or vomiting (TIN+/−V)—remains elusive for several reasons. Potentially, N&V may be part of a symptom cluster where co-occurring symptoms negatively affect antiemetic management. Consequently, we examined TIN+/−V incidence and the impact of nausea, vomiting and symptom cluster(s) containing them, respectively, on patients’ quality of life (QoL) and psychological adjustment across treatment.